3/14 Taiwan Life Sciences Biweekly Newsletter2022-03-16
Taiwan Life Sciences Biweekly
|1. TaiMed Biologics : Expands Its Business Model from Biologic DrugInnovator to Contract Development and Manufacturing Organization(CDMO).More...
|2. Formosa Plastics Biomedical enters the field of cell therapy
1 March, 2022
Formosa Plastics Group (TW: 1301) announced that its subsidiary Formosa Biomedical had entered the growing field of cell therapy by acquiring 62,342,000 shares of Taoyuan, Taiwan-based cell therapy firm Ivy Life Sciences Corporation for NTD755 million to at an average cost of NTD12.1 per share. More... (in Chinese)
|3. Lotus Pharmaceutical cancer drugs receive Philippine drug approval
1 March, 2022
Taipei, Taiwan-headquartered specialty pharmaceutical company Lotus Pharmaceutical (TW: 1795), announced that its two major cancer drugs, Lenalidomide (Revlimid) and Gefitinib (Iressa), have successively obtained drug approval in the Philippines. The company stated that it was the first and currently the only company licensed to sell Lenalidomide in the Philippines, with the potential market size of Lenalidomide in the Philippines is expected to reach about USD10 million. More... (in Chinese)
|4. PharmaEssentia’s BESREMi (Ropeginterferon alfa-2b) included in new US NCCN treatment guidelines
1 March, 2022
Taipei, Taiwan-headquartered PharmaEssentia announced that the US National Comprehensive Cancer Network (NCCN) had listed its new drug BESREMi® (Ropeginterferon alfa-2b, Ropeg) as a treatment option for hyperplasia (PV), in both high- and low-risk PV patients. In a statement with this announcement, PharmaEssentia noted that NCCN diagnosis and treatment guidelines are recognized clinical standards for cancer management. More... (in Chinese)
|5. Precision Health concepts key to building a strong nation: Ministry of Health and Welfare
28 February, 2022
With the passing of the third reading of regulatory framework governing Taiwan’s biomedical industry, the Act for the Development of Biotech and New Pharmaceuticals Industry, ’precision health’ can now be developed and promoted as the foundation for healthcare in Taiwan, according to Chung-Liang Shih, vice minister of Taiwan’s Ministry of Health and Welfare (MoHW). Precision health concepts involve a personalized approach to medicine, from preventative right through to long-term and aged health care. Shih also pointed out that Taiwan’s burgeoning digital health industry will play an important role in the development of precision health and in protecting the health of the people of Taiwan. More... (in Chinese)
|6. International artificial reproduction services to be reopened in March, along with medical tourism services
27 February, 2022
Taiwan’s Central Epidemic Command Center, a unit of the Center for Disease Control (CDC), announced that it will relax the entry of non-national business travelers from March 7, and after suspending artificial reproduction international medical services for 10 months due to the COVID-19 pandemic will once again open these services for international visitors. Making the announcement, Chung-Liang Shih, vice minister of Taiwan’s Ministry of Health and Welfare (MoHW), said that other medical services targeting overseas visitors will also be available starting 7 March. More... (in Chinese)
|7. MOEA Supports ITRI to Launch iPMx Molecular Rapid Test System for COVID-19 in Japan with BizLink and Japan Biotechno Pharma
25 February, 2022
The iPMx Molecular Rapid Test System, developed by the Industrial Technology Research Institute (ITRI) with the support of Department of Industrial Technology (DoIT), Ministry of Economic Affairs, R.O.C. (MOEA), will be introduced to the Japanese market via the cooperation involving BizLink Group and Japan Biotechno Pharma (JBP). iPMx has received a sales and manufacturing license from Japan's Ministry of Health, Labour and Welfare and is ready to launch in Japan. In the future, the system is expected to further expand its applications and become available for more hospitals and medical facilities overseas. More...
|8. Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
23 February, 2022
Foresee Pharmaceuticals Co., Ltd. (6576.TWO), a Taiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and commercialization in Turkey and certain MENA countries of Foresee's FP-045 program, an oral allosteric Aldehyde Dehydrogenase 2 (ALDH2) activator for the treatment of Fanconi Anemia and other rare and severe diseases. More...
|9. Taiwan welcomes Moderna's plan to set up subsidiary: health minister
16 February, 2022
Taiwan welcomes an announcement by American biotechnology company Moderna, Inc. that it would establish a subsidiary in the country and is open to potential opportunities for cooperation, Health and Welfare Minister Chen Shih-chung said Wednesday. More...
|10. Hon Hai eyes digital healthcare device market in Southeast Asia
15 February, 2022
Taiwan-based manufacturing giant Hon Hai Precision Industry Co., which has intensified efforts to extend its reach beyond contract production, has set its sights on the Southeast Asian market for digital healthcare devices, a senior company official said Tuesday. More...